Jingfeng Pharmaceutical's financial performance since the third quarter of 2023 has shown some changes and trends. First of all, in terms of per share indicators, basic earnings per share and non-earnings per share fluctuated in multiple quarters, and in some quarters were negative, indicating that the company's profitability is somewhat unstable. However, the steady growth of net assets per share indicates that the company has made some progress in asset accumulation.
In terms of growth capacity, the year-on-year growth rate of total operating income has been negative for many quarters, especially in the third quarter of 2023. The year-on-year attributable net profit growth margin was also negative in several quarters, indicating that the company is facing challenges in terms of profits. However, the year-over-year growth rate before non-recurring factors was positive in some quarters, indicating that the company's earnings position adjusted for non-recurring factors was relatively good.
In terms of profitability, ROE and ROE were negative in several quarters, especially the poor ROE performance, indicating that the company's profitability was relatively weak. Gross margin remained high in most quarters, but net profit margin was negative in some quarters, requiring the company to focus on cost management and earnings quality.
In terms of earnings quality, net cash flow from sales Total Operating Income and Net Operating Cash Flow Total operating income was positive for several quarters, indicating that the company is relatively good at converting earnings into cash. The ETR has outliers in certain quarters that require further interpretation and adjustment by the company.
In terms of financial risk, the current ratio and quick ratio have remained relatively reasonable for several quarters, but the company's current ratio is slightly lower, and there is a need to focus on short-term solvency. The gearing ratio fluctuates from quarter to quarter, but generally remains at a high level, and companies need to pay attention to the level of financial leverage.
Finally, in terms of operating capacity, the total asset turnover days, inventory turnover days and accounts receivable turnover days all show certain fluctuations, and the company needs to pay attention to the asset operation efficiency. Total Asset Turnover, Inventory Turnover, and Accounts Receivable Turnover vary from quarter to quarter, requiring further analysis of the company's operations.
Overall, Jingfeng Pharma has faced a number of challenges over the past few quarters, including unstable profitability, financial risks and operational efficiency of its assets. The company needs to respond to market changes and ensure sustainable development by further optimizing its business structure, improving profitability and improving its financial structure.